Although it is well established that parathyroid hormone and phosphate are important regulators of 1,25-dihydroxyvitamin D 11,25(OH)2D] production, it remains unclear whether calcitonin affects vitamin D metabolism in vivo. Experiments were performed in the rat to determine the effect of chronic calcitonin infusion (0.2 U. h-') on plasma levels of vitamin D metabolites and on calcium metabolism. Thyroparathyroidectomized animals fed a calcium-replete or calcium-free diet were studied for as long as 2 wk before they were killed. In control rats, a calciumfree diet alone for 12 d resulted in an increase in 1,25(OH)2D levels from 24±5 to 139±37 pg * ml-', P = 0.025. The infusion of calcitonin also stimulated 1,25(OH)2D levels compared with controls on a regular diet (80±17 vs. 38±6 pg-ml-', P < 0.05) and on a calcium-free diet (460±50 vs. 139±37 pg -ml-', P < 0.001). In addition, calcitonin increased plasma calcium levels in animals on a regular diet by 50%; this effect was most likely due to increased intestinal absorption of calcium, because removal of calcium from the diet markedly blunted this effect. In contrast, calcitonin administration did not significantly affect 25(OH)D plasma levels. Collectively, these data suggest that calcitonin and calcium are independent regulators of 1,25(0H)2D production and that calcitonin stimulates intestinal absorption of calcium, by increasing circulating levels of 1,25(OH)2D.
Introduction
Although it is well known that acute administration of calcitonin causes hypocalcemia and hypophosphatemia, the effect of calcitonin on vitamin D metabolism is unclear. Galante and associates (1) reported that infusion of calcitonin increased the production of 1,25-dihydroxyvitamin D [1,25(0H) 2D]' in the vitamin D-deficient rat. This finding, however, was not confirmed by other workers in the vitamin D-deficient chick (2) or in the thyroparathyrodectomized (TPTX) rat (3) . Recent studies by Horiuchi and associates (4) 25 (OH)D-la-hydroxylase, in vitro, in the proximal straight tubule of rat kidney. However, the interpretation of these studies is confounded by the use of vitamin D-deficient animals, because vitamin D deficiency generated prior to TPTX alters la-hydroxylase activity, and by experimental conditions in which changes in plasma levels of calcium, phosphate, or parathyroid hormone, three independent modulators of 1,25(OH)2D formation, are present.
The present studies were therefore performed to determine whether chronic infusion of calcitonin directly stimulates 1,25(OH)2D generation in vivo, independently of parathyroid hormone, vitamin D deficiency, or changes in plasma levels of calcium or phosphorus. The results show that calcitonin directly stimulates 1,25(OH)2D production which, in turn, increases intestinal absorption of calcium.
Methods
Male Sprague-Dawley rats from Camm Research Laboratories (Wayne, NJ) were used in all experiments, and weighed 220-290 g. Thyroparathyroidectomy (TPTX) was performed under microscopic vision and ether anesthesia, and the glandular tissue was removed by blunt dissection. Adequacy of the procedure was assessed by the level of serum calcium after a 16-h fast on the second day after surgery. Animals were selected for further study only if serum calcium was below. 1.75 mmol * liter-'.
Normal serum calcium was 2.48±0.04 (mean±SEM, n = 30) mmol * liter-'. All TPTX animals were administered 4 ,ug of L-thyroxin (Levotyroid, Armour Pharmaceutical Co., Kankakee, IL) three times weekly, as previously described (6) . Four groups ofanimals were studied: Group A. This group was fed a regular diet and received no infusion. Group B. This group was also fed a regular diet and was infused with salmon calcitonin (Calcimar, Armour Pharmaceutical Co.) at a constant rate of 0.2 U * h-' (MRC international units).
Group C. These animals were fed a calcium-free diet and received no infusion.
Group D. These animals were also fed a calcium-free diet and were infused with salmon calcitonin at a constant rate of 0.2 U* h-'.
Calcitonin was administered by osmotic minipumps (model 2002, Alzet, Palo Alto, CA). The pumps were implanted subcutaneously in the interscapular space under pentobarbital anesthesia (5 mg 100 g body wt-'). A sham implantation was performed under similar conditions in animals that did not receive the hormone infusion.
The experimental diets were begun at the time of implantation. The regular diet was autoclavable rodent laboratory chow No. 5010 (Ralston Purina Co., St. Louis, MO), and contained 1.2% Ca, 0.8% P, and 8.8 IU vitamin D per g of food. The calcium-free food was prepared in our laboratory, as previously described (7), and contained 0.001% Ca, 0 on a calcium and phosphorus-sufficient diet had an average plasma 1,25(OH)2D concentration of 79±23 pg. ml' (mean±SD, n = 7).
Calcium and inorganic phosphorus were measured by spectrophotometry, the former using cresolphtalein complexone (9) and the latter by a modification ofthe technique by Daly and Ertingshausen (10) using ammonium molybdate.
Results are presented both as individual data and as mean±SEM. Statistical comparisons were performed by the paired and unpaired Student's T tests; a P < 0.05 was considered to be significant.
Results
The plasma calcium levels of individual animals followed for 6 or 12 d are shown in Fig. 1 On the calcium-free diet plasma calcium levels remained low, and gradually fell during the course of the study in the shamimplanted animals ( Fig. 1 C) . In contrast to the calcitonin-treated group on a regular diet, the calcitonin-treated group on the calcium-free diet was characterized by persistent hypocalcemia through day 12 ( Fig. 1 D) , although calcium levels increased by 15% by day 12 (P < 0.02) compared with day 0. Plasma phosphate levels of individual animals are depicted in Fig. 2 . It is apparent that the procedure of TPTX resulted in hyperphosphatemia in all animals and that plasma phosphate levels were not significantly altered during the period of observation in any of the groups. Rats in group B. however, were found to have slightly lower plasma phosphate levels than rats in the other groups by the end of the follow-up period, probably owing to the higher plasma calcium levels recorded in these animals. It Figure 2 . Plasma phosphate levels in the same experimental groups described in Fig. 1 . Fig. 2 A) or presence (3.80±0.15 mmol/liter, n = 9, Fig. 2 B) of calcitonin.
In that an escape phenomenon or loss of effectiveness of calcitonin on bone metabolism has been reported during chronic administration ( 11) , studies were performed to determine whether tolerance to the action of calcitonin had occurred after 6 or more days of treatment. As shown in Fig. 3 , the administration of a bolus of 1 or 10 U of calcitonin on days 6 8 .0±1.8 ng ml-' (control) and 5.6±1.1 (calcitonin), P = NS, whereas on a calcium-free diet the levels were 5.3±0.3 ng ml-' (control) and 9.2±1.9 (calcitonin), P = NS. Inspection of Fig.  4 , shows that 1,25(OH)2D levels were influenced by both the dietary regimens and calcitonin. In control animals plasma 1,25(OH)2D levels increased by day 12 from 24±5 on regular diet to 139±37 pg ml-' (P = 0.025) on calcium-free diet, indicating a direct stimulatory effect of calcium depletion on production of this hormone. A stimulatory effect of calcitonin on 1,25(OH)2D production was demonstrated on both dietary regimens. At day 6 on the regular diet plasma levels of 1,25(OH)2D were higher in the calcitonin-infused animals, than in untreated counterparts (80±17 vs. 38±6 pg ml-', P < 0.05); at day 12 on this diet, however, the levels of 24±5 and 28+1 pg* ml-' in the same groups, respectively, were not statistically different. At day 12 on the calcium-free diet plasma levels of 1,25(OH)2D were higher in the calcitonin-infused than in the untreated rats (460±50 pg * ml-' vs. 139±37, P < 0.001). Inasmuch as the group treated with calcitonin on the regular diet was relatively hypercalcemic on day 12, it seems likely that 1,25(OH)2D production was suppressed by the increased plasma calcium levels. In contrast, in the group on the calcium-free diet the stimulatory action of calcitonin was unimpeded because calcium levels persisted in a hypocalcemic range. (16) .
Discussion
It was of interest that further treatment of animals on a regular diet for 13 d was not associated with a sustained elevation of 1,25(OH)2D levels. This was probably due to higher plasma levels of calcium compared with control, as apparent from inspection of Fig. 1 B: clearly the rise in plasma calcium levels and/or body stores of calcium were large enough to offset the stimulation of 25(OH)D-1 a-hydroxylase. After removal of calcium from the diet to blunt the increase in plasma calcium, the 1,25(OH)2D levels rose approximately fivefold in controls (139±37 vs. 24±5 pg ml-') and nearly 19 -fold in calcitonintreated animals (460±50 vs. 28±1 pg-ml-'). These results therefore, indicate that calcium, as well as calcitonin, influence 1,25(OH)2D production.
An additional finding of special interest in the present study was that chronic calcitonin administration in animals on a reg-ular diet increased plasma calcium levels, an effect that did not occur until approximately day 5 ofinfusion. This calcium-raising effect of calcitonin might, at first, seem paradoxical since numerous previous studies have shown that acute administration of calcitonin decreases plasma calcium, owing to an inhibition of bone resorption. The acute effect of calcitonin to decrease plasma calcium was also demonstrated in the present study, in experiments in which acute bolus infusion was superimposed on chronic calcitonin infusion (shown in Fig. 3 ). The present study shows that the rise in plasma calcium was primarily caused by increased intestinal calcium absorption, because the increase in plasma calcium was blunted by removal of calcium from the diet.2 It seems likely therefore that the effect of calcitonin on intestinal calcium absorption was mediated by stimulation of 1,25(OH)2D production, although a direct effect of calcitonin on intestinal calcium transport could have also been invoked. However, such an effect has been carefully evaluated in several in vivo and in vitro acute studies which all led to negative results (19) (20) (21) (22) (23) (24) .
Although Woodhouse and associates (25) previously reported that intestinal calcium excretion decreased in patients with Paget's disease during long-term treatment with intermittent boluses ofcalcitonin, an observation consistent with increased intestinal calcium absorption, these data provide the first demonstration that chronic calcitonin infusion increases plasma calcium levels in vivo.
Finally, it was ofinterest that in the calcitonin-treated animals fed the calcium sufficient diet, plasma calcium levels remained elevated (i.e., within the normal range of values) through day 13 although on that day the level of 1,25(OH)2D was not statistically different from control. This apparent inconsistency with the notion that the rise in plasma calcium was caused by increased intestinal absorption of calcium due to elevated levels of 1,25(OH)2D is probably explained by the considerable time lag between the disappearance rate ofthe hormone from plasma and loss of its biologic effect (26-29), especially in hypoparathyroidism (30) .
In conclusion this study suggests that, in addition to parathyroid hormone and phosphate stores, calcitonin and calcium qualify as independent regulators of 1,25(OH)2D production. Moreover, during chronic administration of calcitonin plasma calcium levels are increased due to a rise in intestinal calcium absorption brought about by enhanced levels of 1,25(OH)2D. These observations may have important clinical implications since they may provide an explanation, at least in part, for the apparent tolerance to the hypocalcemic effect of calcitonin that has been described during long-term treatment.
